118
Participants
Start Date
March 29, 2021
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2029
Difluoromethylornithine
"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
RECRUITING
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RECRUITING
Levine Children's Hospital, Charlotte
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Arnold Palmer Hospital for Children, Orlando
RECRUITING
St. Joseph's Children's Hospital, Tampa
RECRUITING
University of Louisville/Norton's Children's, Louisville
RECRUITING
Kentucky Children's Hospital, Lexington
NOT_YET_RECRUITING
Cardinal Glennon Children's Medical Center, St Louis
RECRUITING
Children's Mercy Hospitals and Clinics, Kansas City
RECRUITING
Arkansas Children's Hospital, Little Rock
RECRUITING
Dell Children's Blood and Cancer Center, Austin
RECRUITING
Rady Children's Hospital, San Diego
RECRUITING
UCSF Benioff Children's Hospital Oakland-, Oakland
NOT_YET_RECRUITING
Connecticut Children's Hospital, Hartford
RECRUITING
Hackensack University Medical Center, Hackensack
Giselle Sholler
OTHER